China approves emergency usage of COVID-19 vaccines

China approves emergency usage of COVID-19 vaccines

The Phase 2/3 trial is designed as a 1:1 investigational vaccine candidate to placebo, randomized, observer-blinded study to obtain safety, immune response, and efficacy data needed for regulatory review for this unique vaccine development approach, which uses mRNA packaged with coronavirus genes to generate the spike protein which is believed to generate protective antibodies. According to ClinicalTrials.gov, Sputnik V (under its old name of Gam-COVID-Vac) was tested in an open, two-stage, non-randomized Phase I/II trial (NCT04436471) that recruited just 38 participants, all healhy volunteers.

The first person to volunteer for the vaccine, a 50-year-old woman, was inoculated at 08.30 this morning at the Spallanzani, a specialist centre for infectious diseases which has played a central role in battling Italy's coronavirus crisis.

Earlier this month, the Australian government announced that it has signed a letter of intent with AstraZeneca to secure a supply of the vaccine candidate.

The authorities of this town in China assured in a statement that this vaccine had been shown to be effective against the disease in trials with monkeys, without causing any kind of side effect.

The Covax Facility is a Gavi-coordinated pooled procurement mechanism for new Covid-19 vaccines, through which Covax will ensure fair and equitable access to vaccines for each participating economy, using an allocation framework now being formulated by WHO.

Overall, the stock scores a Strong Buy consensus from the analyst community based on 3 back-to-back buy ratings. "Belarus will thus become the first nation to import the Russian vaccine", the press service said.

ReiThera's novel GRAd vector belongs to species C adenovirus that are considered the most potent vaccine carriers and has low seroprevalence in humans. Nine candidate vaccines are now being supported by CEPI; seven of which are now in clinical trials.

China's coronavirus vaccines will be priced close to cost, Zheng said. The country is expecting to produce about 1-5 million to 2 million doses every month by the end of the year 2020.

Zheng Zhongwei, the head of China's coronavirus vaccine development task force, told state-controlled CCTV that the emergency use authorization has been active for select candidates developed by domestic companies.

This came after a series of measures were set out to ensure that emergency use of the vaccines is well regulated and monitored, he said.

In the U.S., President Donald Trump is also mulling over issuing an emergency use authorization (EUA) for AstraZeneca-Oxford University co-developed vaccine candidate before the elections in November.

An inactivated COVID-19 vaccine developed by China has started phase-3 clinical trials in Argentina, according to its developer China National Biotec Group (CNBG), which is affiliated to Sinopharm.

Related Articles